文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

不可切除胰腺癌患者ERCP使用趋势:SEER-Medicare数据库研究

Trends in performance of ERCP among patients with surgically unresectable pancreatic cancer: a Survival, Epidemiology and End Results-Medicare database study.
PubMed 文献 · Gastrointest Endosc · 2021-04-20

基于SEER-Medicare数据库纳入2000至2015年诊断的不可手术胰腺头腺癌患者14,810例,53%在诊断前后30天内接受ERCP。

要点

  • 不可切除胰腺头癌患者诊断前后30天内ERCP使用比例为53%。
  • ERCP使用比例从2001年57%降至2015年46%,呈显著下降趋势。
  • 尽管ERCP使用减少,调整后1年生存率随时间改善。

核心结论

  • 2001至2015年间,不可切除胰腺癌患者接受ERCP的比例及人均ERCP次数均下降,但生存率改善。

主要发现

  • 53%(7034/14,810)的患者在癌症诊断前后30天内接受ERCP。
  • 尽管ERCP使用下降,调整后1年生存率随时间改善。

临床怎么用

  • 不可切除胰腺头癌伴胆道梗阻患者中ERCP使用比例下降,临床决策需结合生存改善趋势综合评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with biliary obstruction caused by adenocarcinoma of the pancreas head may require bile duct decompression to treat symptomatic cholestasis and/or permit systemic chemotherapy. ERCP with biliary stent placement is the preferred intervention in such cases. The primary aim of this study was to determine what proportion of patients with surgically unresectable pancreatic adenocarcinoma undergo ERCP and whether this proportion has changed over time. METHODS: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked data to identify a cohort of individuals diagnosed with adenocarcinoma of the pancreas head between December 31, 2000 and December 31, 2015 and who did not receive pancreas surgery. ERCP use was measured in the 30 days before and after cancer diagnosis. Additional covariates of interest were extracted for multiple variable analysis. RESULTS: A total of 14,810 patients met study inclusion and exclusion criteria. Of them, 53% (7034/14,810) underwent ERCP within 30 days of cancer diagnosis. The proportion of patients who underwent ERCP declined from 57% in 2001 to 46% in 2015 (P for trend < .001). Among those who underwent ERCP, the mean number of ERCPs performed per patient over the year after diagnosis declined from 2.3 (standard deviation, 1.6) in 2001 to 1.8 (standard deviation, 1.1) in 2015 (P < .001). Despite decline in ERCP use, adjusted 1-year survival increased over time. CONCLUSIONS: In a SEER-Medicare population between 2001 and 2015, both the proportion of patients with unresectable pancreas cancer who underwent ERCP and the mean number of ERCPs per patient decreased over time. Survival improved over time despite decreased use of ERCP.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Yachimski P, Lucas A, Dusetzina SB, et al. Trends in performance of ERCP among patients with surgically unresectable pancreatic cancer: a Survival, Epidemiology and End Results-Medicare database study. Gastrointest Endosc. 2021. PMID: 33862104. doi:10.1016/j.gie.2021.03.998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。